https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Pharmaceutical-Tech_nervecells.jpg400605Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-10 08:01:152026-08-14 14:44:41NRG raises Series A funds for Parkinson’s and ALS therapy development
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/methode_sundaytimes.jpg450800Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-10 08:00:202026-08-14 14:47:07Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/scan_pic.jpg400605Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:05:142026-08-14 16:03:58NRG announces £16m Series A for IND for Parkinson’s and ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Roadway.jpg400605Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:04:022026-08-14 16:06:49Following the path to a new drug, together
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/admin_biospace.jpg400605Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:03:432026-08-14 16:09:06NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson’s, ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Business-Weekly-logo-300x135-1.jpg310524Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:02:452026-09-10 10:27:34Omega Funds leads £16m Series A round for NRG Therapeutics
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/bioworld-logo-vector.jpg8431500Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:01:562026-08-14 16:11:45NRG closes £16M series A to fund fight against neurodegenerative diseases
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/BusinessWeekly_NRG.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:00:562026-08-14 16:12:46GSK vets theorize that a mitochondrial target may unlock Parkinson’s and ALS treatments in new startup
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/bioworld-logo-vector.jpg8431500Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-08-31 08:00:422026-09-09 17:40:56NRG gearing up for series A to advance brain-penetrant PTP inhibitors
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/QW04Z4YLERS41E7A85IO.jpg437750Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-07-07 08:00:252026-08-14 16:20:20NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/shutterstock-mitochondria.jpg6831024Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-06-30 08:00:392026-08-14 16:22:31NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders
NRG raises Series A funds for Parkinson’s and ALS therapy development
Pharmaceutical Technology
Read more
Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS
Labiotech
Read more
NRG announces £16m Series A for IND for Parkinson’s and ALS
PharmaPhorum
Read more
Following the path to a new drug, together
Parkinson’s UK
Read more
NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson’s, ALS
Biospace
Read more
Omega Funds leads £16m Series A round for NRG Therapeutics
Business Weekly
NRG closes £16M series A to fund fight against neurodegenerative diseases
Bioworld
Read more
GSK vets theorize that a mitochondrial target may unlock Parkinson’s and ALS treatments in new startup
Endpoints
Read more
NRG gearing up for series A to advance brain-penetrant PTP inhibitors
Bioworld
Read more
(behind a paywall)
NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease
Cambridge Independent
Read more
NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
PMLive
Read more
NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders
Labiotech
Read more